New Osteoporosis Treatment Options on the Horizon

Share this content:

Nancy E. Lane, MD, professor of medicine, and director of the Center for Musculoskeletal Health at the University of California at Davis School of Medicine, sat down with Rheumatology Advisor at the American College of Rheumatoloy annual meeting to discuss results from a phase 3 trial evaluating the safety and efficacy of a parathyroid hormone-related peptide analog in preventing fractures in postmenopausal women with severe osteoporosis (Abaloparatide Comparator Trial In Vertebral Endpoints "ACTIVE", Identifier NCT01343004). 

You must be a registered member of Endocrinology Advisor to post a comment.

Sign Up for Free e-Newsletters

CME Focus